Apax acquires majority shareholding in metaGen
With E42m from Apax in the bank, the biotech company will continue to develop new strategies for cancer therapy.
29 December 2012•2 mins read
With E42m from Apax in the bank, the biotech company will continue to develop new strategies for cancer therapy.
AllianzGI leaves door open for reversal of PE pullback
5 November 2026 · 2 mins read
How Schroders’ $30bn PE funds platform is growing its CV and co-invest allocations
5 November 2026 · 4 mins read
Side Letter: Johns, jitters, judgment calls
4 November 2026 · 5 mins read
Rothschild & Co’s private client unit seeks to rebalance PE portfolio
4 November 2026 · 2 mins read
Weil wind-down: How fund mandates will be affected
4 November 2026 · 4 mins read
Side Letter: Blended buyouts
3 November 2026 · 3 mins read
Blackstone’s Gray: Some AI investments 'will go awry'
3 November 2026 · 3 mins read
